Mirati Therapeutics (MRTX) Announces $700M Proposed Public Offering of Common Stock

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its common stock and a selling stockholder intends to offer 375,000 shares in the offering. In addition, Mirati and the selling stockholder expect to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the total shares offered in the public offering at the public offering price, less the underwriting discounts and commissions. Mirati will not receive any proceeds from the sale of shares in the offering by the selling stockholder. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman Sachs & Co. LLC, SVB Leerink LLC, Cowen and Company, LLC and Evercore Group, L.L.C. are acting as joint book-running managers in the offering.

The securities described above are being offered pursuant to a shelf registration statement filed by Mirati with the Securities and Exchange Commission ("SEC") that became automatically effective upon filing.

You May Also Be Interested In

• Robinhood prices $2B convertible notes offering due 2029
• NVE Corporation names new CEO and expands board to seven members
• TaskUs names Rishabh Khemka as CFO, effective June 2026